Zurampic

1

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



2

This medicinal product is subject to additional monitoring. This will allow quick identification of 
new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 
See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Zurampic 200 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 200 mg of lesinurad.

Excipient with known effect: Each tablet contains 52.92 mg of lactose (as monohydrate).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).

Oval, 5.7 x 12.9 mm, blue tablets.

Tablets are engraved with “LES200” on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive 
treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target 
serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

4.2 Posology and method of administration

Posology

The recommended dose of Zurampic is 200 mg once daily in the morning. This is also the maximum 
dose (see section 4.4).

Zurampic tablets must be co-administered at the same time as the morning dose of a xanthine oxidase 
inhibitor, i.e. allopurinol or febuxostat. The recommended minimum dose of allopurinol is 300 mg, or 
200 mg for patients with moderate renal impairment (creatinine clearance [CrCL] of 30-59 mL/min). If 
treatment with the xanthine oxidase inhibitor is interrupted, Zurampic dosing must also be interrupted.

Patients should be informed that failure to follow these instructions may increase the risk of renal 
events (see section 4.4).

Patients should be instructed to stay well hydrated (e.g. 2 litres of liquid per day).

The target serum uric acid level is less than 6 mg/dL (360 µmol/L). In patients with tophi or persistent 
symptoms, the target is less than 5 mg/dL (300 µmol/L). Testing for the target serum uric acid level 
may be performed as early as 4 weeks after initiating Zurampic treatment.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



3

Gout flare prophylaxis with colchicine or a nonsteroidal anti-inflammatory drug (NSAID) is 
recommended for at least 5 months when starting therapy (see section 4.4).

Special populations

Elderly (≥65 years)
No dose adjustment is necessary based on age (see section 5.2); however, elderly patients are more 
likely to have decreased renal function (see dosing recommendations for renal impairment).
Experience in very elderly (≥75 years) is limited (see section 4.4).

Renal impairment
Zurampic must not be initiated in patients with severe renal impairment (CrCL less than 30 mL/min), 
with end-stage renal disease or in patients on dialysis (see sections 4.3 and 4.4). Based on its 
mechanism of action, lesinurad may not be effective in these patients (see section 5.1). Zurampic 
should not be initiated in kidney transplant recipients.

No dose adjustment is necessary in patients with mild or moderate renal impairment (CrCL of 
30-89 mL/min) (see sections 4.8, 5.1 and 5.2). Zurampic should be used with caution in patients with a 
CrCL of 30 to less than 45 mL/min (see section 4.4).

Hepatic impairment
No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh 
classes A and B) (see section 5.2). Zurampic has not been studied in patients with severe hepatic 
impairment; therefore, dose recommendations cannot be given.

Paediatric population
The safety and efficacy of Zurampic in children under 18 years of age have not yet been established.
No data are available.

Method of administration

Oral use.

Zurampic should be taken in the morning with food and water.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients with tumour lysis syndrome or Lesch-Nyhan syndrome.

Severe renal impairment (CrCL less than 30 mL/min), end-stage renal disease, kidney transplant 
recipients or patients on dialysis (see section 4.2).

4.4 Special warnings and precautions for use

Renal events
Treatment with lesinurad 200 mg in combination with a xanthine oxidase inhibitor was associated with 
an increased incidence of serum creatinine elevations, which are related to increased renal uric acid 
excretion. Adverse reactions related to renal function can occur after initiating Zurampic (see section 
4.8). A higher incidence of serum creatinine elevations and renal-related adverse reactions including 
serious adverse reactions was observed with Zurampic 400 mg when given alone or in combination 
with a xanthine oxidase inhibitor, with the highest incidence when Zurampic was given as 
monotherapy. Zurampic should not be used as monotherapy or at doses above the recommended dose.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



4

Experience with Zurampic in patients with an estimated CrCL (eCrCL) less than 45 mL/min is limited;
therefore, Zurampic should be used with caution in patients with a CrCL from 30 mL/min to less than 
45 mL/min.

Renal function should be evaluated prior to initiation of Zurampic and monitored periodically 
thereafter, e.g. 4 times per year, based on clinical considerations, such as baseline renal function, 
volume depletion, concurrent illness or concomitant medications. Patients with serum creatinine 
elevations to greater than 1.5 times the pre-treatment value should be closely monitored. Zurampic
should be interrupted if serum creatinine is elevated to greater than 2 times the pre-treatment value or 
in case of an absolute serum creatinine value greater than 4.0 mg/dL. Treatment should be interrupted 
in patients who report symptoms that may indicate acute uric acid nephropathy including flank pain, 
nausea or vomiting, and measure serum creatinine promptly. Zurampic should not be restarted without 
another explanation for the serum creatinine abnormalities.

Pre-existing cardiovascular disease
Zurampic is not recommended in patients with unstable angina, New York Heart Association (NYHA) 
class III or IV heart failure, uncontrolled hypertension or with a recent event of myocardial infarction, 
stroke, or deep venous thrombosis within the last 12 months, due to insufficient data. For 
cardiovascular patients in a stable condition, the benefit/risk balance should be assessed for each 
individual patient on an ongoing basis, taking into account the benefits of lowering urate levels versus 
a potential increase in cardiac risk (see section 4.8).

Acute gouty attacks (gout flares)
Gout flares may occur after initiation of therapy with Zurampic. This is due to reduction in serum uric 
acid levels resulting in mobilisation of urate from tissue deposits. Gout flare prophylaxis with 
colchicine or an NSAID is recommended for at least 5 months when starting Zurampic therapy (see 
section 4.2).

Zurampic does not need to be discontinued because of a gout flare. The gout flare should be managed 
concurrently as appropriate for the individual patient. Continuous treatment with Zurampic decreases 
the frequency of gout flares.

Effect of CYP2C9 genotype
Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk 
of renal-related adverse effects may be increased (see sections 4.8 and 5.2). 

Clinically relevant interactions with other medicinal products

CYP3A substrates
Lesinurad is a mild to moderate inducer of CYP3A (see section 4.5). An induction effect of lesinurad 
should be anticipated after 2 to 3 weeks of continuous co-administration of Zurampic. Additional 
monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate 
lipid lowering medicines (such as lovastatin or simvastatin) or antihypertensive medicines (such as 
amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5).

Hormonal contraceptives 
Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be 
reliable when Zurampic is co-administered. Female patients of childbearing age should practice 
additional methods of contraception and not rely on hormonal contraception alone when taking 
Zurampic (see sections 4.5 and 4.6).

Very elderly (≥75 years)

Therapeutic experience in patients 75 years and older is limited. Caution should be used when treating 
these patients with Zurampic.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



5

Secondary hyperuricaemia
No studies have been conducted in patients with secondary hyperuricaemia (including organ transplant
recipients).

Lactose intolerance
Zurampic contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp 
lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions

Salicylates
Salicylates at doses higher than 325 mg per day may decrease the serum uric acid lowering activity of 
lesinurad and should not be co-administered with Zurampic. Consistent serum uric acid lowering was 
observed in patients who were receiving low dose acetylsalicylic acid in the placebo-controlled clinical 
studies in combination with allopurinol or febuxostat. There are no restrictions for doses of salicylates 
of 325 mg or less per day (i.e. for cardiovascular protection).

Thiazide diuretics
Consistent serum uric acid lowering was observed in patients who were receiving thiazide diuretics in 
the placebo-controlled clinical studies in combination with allopurinol or febuxostat.

Pharmacokinetic interactions

Effect of lesinurad on other medicinal products

CYP3A substrates
Mild to moderate induction of CYP3A by lesinurad may reduce plasma exposures of co-administered 
medicines that are sensitive substrates of CYP3A. In interaction studies conducted in healthy subjects 
with Zurampic and CYP3A substrates, lesinurad reduced the plasma concentrations of sildenafil and 
amlodipine. HMG-CoA reductase inhibitors that are sensitive CYP3A substrates may interact with 
lesinurad. In the pivotal clinical trials, a greater proportion of patients using lipid lowering or anti-
hypertensive medicines that were CYP3A substrates required concomitant medicinal product change 
when treated with Zurampic 200 mg in combination with a xanthine oxidase inhibitor, compared with 
patients treated with placebo in combination with a xanthine oxidase inhibitor (35% versus 28%, 
respectively). The possibility of reduced efficacy of concomitant medicinal products that are CYP3A 
substrates should be considered and their efficacy (e.g. blood pressure and cholesterol levels) should 
be monitored (see section 4.4). 

Warfarin
In an interaction study conducted in healthy subjects with multiple doses of Zurampic 400 mg and 
single dose warfarin (25 mg), lesinurad led to a decrease in exposure of R-warfarin (the less active 
enantiomer) and had no effect on the exposure of S-warfarin (the more active enantiomer). 
Additionally, lesinurad led to a 6-8% decrease in International Normalised Ratio (INR) and 
Prothrombin Time (PT). The standard INR monitoring schedule should be applied, and no further 
actions are required.

Hormonal contraceptives
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of 
some hormonal contraceptives, thereby decreasing contraceptive effectiveness (see sections 4.4 and 
4.6).

CYP2B6 substrates
Based on in vitro data, lesinurad may be a mild inducer of CYP2B6 but this interaction has not been
studied clinically. Therefore, it is recommended that patients are monitored for reduced efficacy of 
CYP2B6 substrates (e.g. bupropion, efavirenz) when co-administered with Zurampic.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



6

Based on interaction studies in healthy subjects or gout patients, Zurampic does not have clinically 
significant interactions with NSAIDs (naproxen and indomethacin), colchicine, repaglinide,
tolbutamide, febuxostat or allopurinol. Zurampic slightly decreased exposure of oxypurinol (a URAT1 
substrate), the major metabolite of allopurinol; however, the uric acid-lowering effect of the 
combination with allopurinol was significantly greater than for either substance alone.

Effect of other medicinal products on lesinurad

CYP2C9 inhibitors and inducers
Lesinurad exposure is increased when it is co-administered with inhibitors of CYP2C9. Fluconazole, a 
moderate CYP2C9 inhibitor, increased lesinurad AUC (56%) and Cmax (38%), as well as the amount of 
lesinurad excreted unchanged in urine. Other moderate CYP2C9 inhibitors, such as amiodarone, would 
also be expected to affect lesinurad pharmacokinetics to a similar degree. Therefore, it is 
recommended that Zurampic should be used with caution in patients taking moderate inhibitors of 
CYP2C9. Lesinurad exposure is expected to decrease when it is co-administered with inducers of 
CYP2C9 (e.g. carbamazepine, a moderate CYP2C9 inducer). Monitor for decreased efficacy when 
Zurampic is co-administered with a CYP2C9 inducer.

Rifampin
Rifampin, an inhibitor of OATPs and an inducer of CYP2C9, decreased lesinurad exposure and 
slightly reduced the amount of lesinurad excreted unchanged in urine with no clinically relevant effect. 
The lack of an observed interaction could be due to the combination of the induction of CYP2C9 and 
inhibition of OATP1B1 and 1B3.

Epoxide hydrolase inhibitors
Inhibitors of microsomal Epoxide Hydrolase (mEH) (e.g. valproic acid, valpromide) may interfere 
with the metabolism of lesinurad. Zurampic should not be administered with inhibitors of mEH.

4.6 Fertility, pregnancy and lactation

Pregnancy
There are no data from the use of lesinurad in pregnant women. 

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity 
(see section 5.3). 

As a precautionary measure, it is preferable to avoid the use of Zurampic during pregnancy. Female 
patients of childbearing potential should not rely on hormonal contraception alone when taking 
Zurampic (see sections 4.4 and 4.5).

Breast-feeding
Available pharmacodynamic/toxicological data in rats have shown excretion of lesinurad in milk. A 
risk to the newborns/infants cannot be excluded. Zurampic should not be used during breast-feeding.

Fertility
The effect of lesinurad on fertility in humans has not been studied. In rats, there was no effect on 
mating or fertility with lesinurad (see section 5.3).

4.7 Effects on ability to drive and use machines

Lesinurad has no or negligible influence on the ability to drive and use machines.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



7

4.8 Undesirable effects

Summary of the safety profile
The safety of Zurampic 200 mg was evaluated in the Phase 3 combination therapy clinical trials 
(including extension studies). The most commonly reported adverse reactions during treatment with 
Zurampic 200 mg are influenza, gastro-oesophageal reflux disease, headache and blood creatinine 
increased. The serious adverse reactions renal failure, renal impairment and nephrolithiasis have 
occurred uncommonly (less than 1 case per 100 patients) (see Table 1). In clinical trials, most adverse 
reactions were mild or moderate in intensity and resolved while continuing Zurampic therapy. The 
most common adverse reaction leading to discontinuation of Zurampic was blood creatinine increased 
(0.8%).

Tabulated list of adverse reactions

Adverse reactions are classified according to frequency and System Organ Class. Frequency categories 
are defined according to the following conventions: very common (≥1/10), common (≥1/100 to <1/10), 
uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000) and very rare (<1/10,000).

Table 1 lists adverse reactions identified in clinical studies with patients receiving Zurampic 200 mg 
once daily in combination with a xanthine oxidase inhibitor, allopurinol or febuxostat.

Table 1 Adverse reactions by System Organ Class and frequency

System Organ Classification Common Uncommon Rare

Infections and infestations Influenza

Immune system disorders Hypersensitivity*

Metabolism and nutrition 

disorders

Dehydration

Nervous system disorders Headache

Gastrointestinal disorders Gastro-oesophageal

reflux disease

Renal and urinary disorders Renal failure**

Renal impairment

Nephrolithiasis

Investigations Blood creatinine 

increased

*Photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria.
**Includes the preferred terms: renal failure, renal failure chronic and renal failure acute. 

Description of selected adverse reactions

Renal events
Zurampic causes an increase in renal uric acid excretion, which may lead to transient increases in 
serum creatinine, renal-related adverse reactions and kidney stones. Although other doses have been 
studied, the recommended dose of Zurampic is 200 mg once daily in combination with a xanthine 
oxidase inhibitor.

In three 12-month placebo-controlled trials of Zurampic in combination with a xanthine oxidase 
inhibitor versus a xanthine oxidase inhibitor alone (placebo), serum creatinine elevations between 1.5-
fold and 2-fold over baseline occurred in 3.9% of patients on Zurampic 200 mg, 10.0% of patients on 
Zurampic 400 mg and 2.3% on placebo; serum creatinine elevations 2-fold or greater over baseline

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



8

occurred in 1.8% of patients on Zurampic 200 mg, 6.7% of patients on Zurampic 400 mg and 0% on 
placebo. These serum creatinine elevations generally resolved, most without treatment interruption. 
Renal-related adverse reactions were reported in patients treated with Zurampic 200 mg (5.7%) and 
Zurampic 400 mg (11.8%) compared to placebo (4.5%), resulting in discontinuation of treatment in 
1.2%, 3.3% and 1%, respectively (see section 4.4). The most frequent renal-related adverse reaction 
was blood creatinine increased (4.3% with Zurampic 200 mg and 7.8% with Zurampic 400 mg 
compared to 2.3% with placebo). In patients with moderate renal impairment, the incidence of renal-
related adverse reactions was similar across all treatment groups: Zurampic 200 mg (12.7%), Zurampic
400 mg (16.3%) and placebo (13.3%). Serious renal-related adverse reactions, e.g. acute renal failure 
and renal impairment, were reported in patients treated with lesinurad 400 mg (1%) and placebo 
(0.4%) and in no patients on lesinurad 200 mg. Including the combination long-term extension studies, 
the incidences of serious renal-related adverse reactions (including acute renal failure) per 100 patient-
years of exposure were 0.4 and 1.4 for Zurampic 200 mg and Zurampic 400 mg in combination with a 
xanthine oxidase inhibitor, respectively (see sections 4.2 and 4.4). Data from the long-term extension 
studies until 24 months revealed a renal safety profile consistent with that observed in the placebo-
controlled studies.

In a 6-month double-blind, placebo-controlled monotherapy study of Zurampic, renal-related adverse 
reactions and serious renal-related adverse reactions (including acute renal failure) were reported in 
17.8% and 4.7% of patients respectively, receiving Zurampic 400 mg alone and in no patients 
receiving placebo (see sections 4.2 and 4.4). Among serious renal-related adverse reactions: renal 
failure, renal failure acute and renal impairment were reported in 1.9%, 1.9% and 0.9% respectively, of 
patients receiving lesinurad 400 mg monotherapy and in no patients receiving placebo. Since the 
incidence of severe renal-related adverse events was increased with the monotherapy as compared to 
the combination therapy with a xanthine oxidase inhibitor, Zurampic should not be used as 
monotherapy (see sections 4.2 and 5.1).

Patients with a history of kidney stones were permitted entry into the 12-month studies of Zurampic in 
combination with a xanthine oxidase inhibitor. In these studies, kidney stone adverse reactions 
(nephrolithiasis being the most frequent) were reported in patients treated with Zurampic 200 mg 
(0.6%), Zurampic 400 mg (2.5%) and placebo (1.7%).

Cardiovascular safety
In the randomised, double-blind, placebo-controlled combination therapy clinical studies, the 
incidences of patients with adjudicated Major Adverse Cardiovascular Events (CV death, non-fatal 
myocardial infarction or non-fatal stroke) per 100 patient-years of exposure were: 0.71 (95% CI 0.23, 
2.21) for placebo, 0.96 (95% CI 0.36, 2.57) for Zurampic 200 mg, and 1.94 (95% CI 0.97, 3.87) for 
Zurampic 400 mg, when used in combination with a xanthine oxidase inhibitor. A causal relationship 
with Zurampic has not been established. All patients with a Major Adverse Cardiovascular Event 
treated with Zurampic 200 mg had a history of heart failure, stroke or myocardial infarction. Post-hoc 
analyses in a subgroup of patients with high cardiovascular risk at baseline (as defined by transient 
ischemic attack, angina pectoris, heart failure, myocardial infarction, peripheral vascular disease 
and/or stroke), showed that the incidence of Major Adverse Cardiovascular Events was 1/52 for 
placebo and 4/53 for Zurampic 200 mg, when used in combination with a xanthine oxidase inhibitor.

Hypersensitivity
Rare cases of hypersensitivity (photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus 
and urticaria) have been reported with lesinurad during the clinical programme. None of these were 
serious or required hospitalisation.

Other special populations

Patients with renal impairment
No overall differences in safety of Zurampic were observed in patients with mild or moderate renal 
impairment (eCrCL of 30-89 mL/min) compared to patients with normal renal function (see sections 
4.2 and 5.2).

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



9

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V.

4.9 Overdose

There is no specific treatment in the event of an overdose, and symptoms of overdose are not 
established. In case of overdose, patients should be managed by symptomatic and supportive care 
including adequate hydration.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antigout preparations, preparations increasing uric acid excretion
ATC code: M04AB05

Mechanism of action
Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1. 
URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular 
lumen. By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric 
acid (sUA). Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced 
hyperuricaemia.

Lesinurad, when combined with a xanthine oxidase inhibitor, increases uric acid excretion and 
decreases uric acid production resulting in greater sUA lowering. Lesinurad should only be used in 
combination with a xanthine oxidase inhibitor because combination use reduces the amount of uric 
acid available for excretion and decreases the risk of renal-related events.

Pharmacodynamic effects
Effects on serum uric acid and urinary excretion of uric acid
In healthy subjects, lesinurad 200 mg lowered sUA levels and increased renal clearance and fractional 
excretion of uric acid. Mean sUA reductions following Zurampic 200 mg administration alone were 
approximately 46% and 26% at 6 hours and 24 hours post-dose, respectively. When Zurampic 200 mg 
was added to a xanthine oxidase inhibitor (i.e. febuxostat), additional 25% and 19% of sUA reductions 
were observed at 6 hours and 24 hours post-dose, respectively.

Effect on cardiac repolarisation
Lesinurad at doses up to 1,600 mg did not demonstrate an effect on ECG parameters (including QTc 
interval) in healthy subjects.

Clinical efficacy and safety
The efficacy of Zurampic 200 mg and 400 mg once daily was studied in 3 multicentre, randomised, 
double-blind, placebo-controlled clinical studies in 1,537 adult patients (13% of these patients were 
elderly, ≥65 years old) with hyperuricaemia and gout in combination with a xanthine oxidase inhibitor, 
allopurinol (CLEAR1 and CLEAR2) or febuxostat (CRYSTAL). All studies were of 12 months 
duration and patients received prophylaxis for gout flares with colchicine or NSAIDs during the first 5 
months of lesinurad treatment.

Based on these studies, Zurampic is only recommended at a dose of 200 mg once daily in combination 
with a xanthine oxidase inhibitor (see sections 4.2 and 4.4).

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



10

Zurampic as add-on to allopurinol in inadequate responders
CLEAR1 and CLEAR2 enrolled patients with gout who were on a stable dose of allopurinol of at least 
300 mg (or 200 mg for moderate renal impairment), had serum uric acid levels greater than 6.5 mg/dL 
and reported at least 2 gout flares in the previous 12 months. Across both studies, 61% of patients had 
mild or moderate renal impairment and 19% had tophi at baseline. Patients continued their allopurinol 
dose and were randomised 1:1:1 to receive Zurampic 200 mg, Zurampic 400 mg, or placebo once 
daily.

The primary efficacy endpoint in both CLEAR1 and CLEAR2 was the proportion of patients 
achieving a serum uric acid target level of less than 6 mg/dL by Month 6. In both studies, significantly 
more patients treated with Zurampic 200 mg in combination with allopurinol achieved the target serum 
uric acid level of less than 6 mg/dL by Month 6 and by Month 12 compared with patients receiving 
placebo in combination with allopurinol (see Table 2).

The stability of the sustained response was demonstrated with a greater proportion of patients treated 
with Zurampic 200 mg in combination with allopurinol achieving the target serum uric acid level at 
each visit for 3 consecutive months (Months 4, 5 and 6) compared to patients treated with placebo in 
combination with allopurinol (see Table 2).

Table 2 Proportion of patients who achieved target serum uric acid levels (<6 mg/dL) with 
Zurampic in combination with allopurinol - Pooled data from CLEAR1 and CLEAR2 
studies

Proportion of patients who met serum uric acid target 
(<6.0 mg/dL)

N (%)

Difference in proportion
(95% C.I.)

Timepoint Placebo + allopurinol

N=407

Zurampic 200 mg + 
allopurinol

N=405

Zurampic 200 mg vs.
placebo

Months 4, 5, 6 48 (12%) 155 (38%)
0.26

(0.21, 0.32)

Month 6 104 (26%) 222 (55%)
0.29

(0.23, 0.36)

Month 12 105 (26%) 203 (50%)
0.24

(0.18, 0.31)

Zurampic when added to allopurinol caused an immediate reduction of the mean serum uric acid 
levels, as compared to placebo, which was sustained in the long term in those patients who continued 
treatment (see Figure 1).

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



11

Figure 1 Mean serum uric acid levels in pooled clinical studies with Zurampic in combination 
with allopurinol in patients with inadequate response (sUA ≥6 mg/dL) to allopurinol 
alone

In each of the studies, a greater proportion of patients treated with Zurampic 200 mg in combination 
with allopurinol compared with placebo in combination with allopurinol achieved a serum uric acid 
less than 5 mg/dL by Month 6 (CLEAR1: 29% versus 10%; CLEAR2: 35% versus 5%).

Zurampic in combination with febuxostat in tophaceous gout
CRYSTAL enrolled gout patients with measurable tophi. Patients received febuxostat 80 mg once 
daily for 3 weeks and then were randomised 1:1:1 to once daily doses of Zurampic 200 mg, Zurampic 
400 mg, or placebo in combination with febuxostat. Sixty-six percent of patients had mild or moderate 
renal impairment. Fifty percent of patients had a baseline sUA ≥5.0 mg/dL, which was after 3 weeks 
of treatment with febuxostat alone.

Zurampic when added to febuxostat caused an immediate reduction of the mean serum uric acid levels, 
as compared to placebo, which was sustained in the long term in those patients who continued 
treatment.

In the subgroup of patients with a baseline sUA ≥5.0 mg/dL, after 3 weeks of febuxostat therapy, a 
significant difference was achieved at all study visits for Zurampic 200 mg in combination with 
febuxostat compared with placebo in combination with febuxostat (see Table 3).

Baseline

Time from Baseline in Months

M
ea

n
 (

S
E

) 
S

er
u

m
 U

ri
c 

A
ci

d
 (

m
g/

d
L

)

Treatment Group: --o-- Placebo + Allopurinol,  Zurampic 200 mg + Allopurinol

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



12

Table 3 Proportion of patients with baseline sUA ≥5.0 mg/dLwho achieve target serum uric 
acid levels (<5 mg/dL) with Zurampic in combination with febuxostat

Proportion of patients who met serum uric acid 
Target (<5.0 mg/dL)

N(%)

Difference in proportion
(95% C.I.)

Timepoint Placebo + febuxostat 
80 mg
N=51

Zurampic 200 mg + 
febuxostat 80 mg

N=59

Zurampic 200 mg vs.
placebo

Months 4, 5, 6 6 (12%) 23 (39%) 0.27
(0.12, 0.42)

Month 6 12 (24%) 26 (44%) 0.21
(0.03, 0.38)

Month 12 12 (24%) 27 (46%) 0.22
(0.05, 0.39)

Primary end-point in patients with renal impairment
Consistent with the overall population, the proportion of patients with mild to moderate renal 
impairment (eCrCL 30-89 mL/min) who achieved target serum uric acid levels at Month 6 was 56% 
for Zurampic 200 mg versus 29% for placebo when added to allopurinol, and 40% for Zurampic 
200 mg versus 26% for placebo when added to febuxostat in patients with baseline sUA ≥5.0 mg/dL.

Clinical outcomes - gout flares requiring treatment
The rates of gout flare requiring treatment were low and comparable to placebo in the last 6 months of 
the randomised trials (after gout flare prophylaxis was discontinued) with median scores of zero. In 
the long-term uncontrolled extension trials, the rates of gout flares requiring treatment further
decreased in the 60% of subjects who entered the extension studies and continued treatment with 
Zurampic 200 mg in combination with allopurinol or febuxostat for up to an additional year of 
treatment.

Clinical outcomes - tophus resolution and reduction
In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% 
resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus 
was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with 
placebo in combination with febuxostat, although the difference was not statistically different (26% 
compared with 21%). After continued treatment of up to 24 months on Zurampic 200 mg in 
combination with febuxostat, the proportion of subjects who experienced complete resolution of at 
least one target tophus increased to 53% of subjects.

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with 
Zurampic in all subsets of the paediatric population for the treatment and prevention of hyperuricaemia 
(see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption
The absolute bioavailability of lesinurad is approximately 100%. Lesinurad is rapidly absorbed after 
oral administration. Following administration of a single oral dose of lesinurad in either the fed or 
fasted state, maximum plasma concentrations (Cmax) were attained within 1 to 4 hours. Cmax and AUC 
exposures of lesinurad increased proportionally with single doses of lesinurad from 5 to 1,200 mg. In 
the fed state, after a single dose of lesinurad 200 mg, geometric mean lesinurad Cmax and AUC were 
6 μg/mL and 29 μg/hr/mL, respectively. There was no apparent influence of the fat content in the meal 
on the pharmacokinetics of lesinurad. In clinical trials, Zurampic was administered with food, because 
the serum uric acid lowering was improved under fed conditions.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



13

Zurampic is administered as a 50:50 mixture of lesinurad atropisomers. The ratio of atropisomer 1 to 
atropisomer 2 AUC(0-24) was 44:56 because atropisomer 1 undergoes more extensive metabolism 
than atropisomer 2, causing atropisomer 1 to have lower plasma exposure than atropisomer 2.

Distribution
Lesinurad is extensively bound to proteins in plasma (greater than 98%), mainly to albumin. Plasma 
protein binding is not meaningfully altered in patients with renal or hepatic impairment. The mean 
steady state volume of distribution of lesinurad was approximately 20 L following intravenous dosing.
Mean plasma-to-blood ratios of lesinurad AUC and Cmax were approximately 1.8, indicating that 
radioactivity was largely contained in the plasma space and did not penetrate or partition extensively 
into red blood cells.

Biotransformation
Lesinurad undergoes oxidative metabolism mainly via cytochrome P450 (CYP) 2C9 to intermediate 
metabolite M3c (not detected in vivo) and is subsequently metabolised by mEH to metabolite M4; 
there is minimal contribution from CYP1A1, CYP2C19, and CYP3A to the metabolism of lesinurad.
Atropisomer 1 is extensively metabolised by CYP2C9 whereas atropisomer 2 is minimally
metabolised by both CYP2C9 and CYP3A4. It is unclear if metabolite plasma exposures are minimal. 
Metabolites are not known to contribute to the uric acid lowering effects of lesinurad.

Elimination
Renal clearance is 25.6 mL/min (CV=56%). Lesinurad is highly protein bound and renal clearance is 
high (as compared to typical human glomerular filtration rate), indicating that active secretion plays an 
important role in the renal excretion of lesinurad. Within 7 days following single dosing of 
radiolabelled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of 
administered radioactive dose was recovered in faeces. Most of the radioactivity recovered in urine 
(>60% of dose) occurred in the first 24 hours. Unchanged lesinurad in urine accounted for 
approximately 30% of the dose. The elimination half-life (t½) of lesinurad was approximately 5 hours 
following a single dose. Lesinurad does not accumulate following multiple doses.

Linearity/non-linearity
Following multiple once daily dosing of Zurampic, there was no evidence of time dependent changes 
in pharmacokinetic properties and dose proportionality was preserved.

In vitro assessment of interactions
Lesinurad is mainly metabolised by CYP2C9 and mEH, and to a lesser extent by CYP1A1, CYP2C19 
and CYP3A. In vitro, lesinurad is an inhibitor of CYP2C8, but not of CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4 and mEH. In addition, lesinurad is an in vitro inducer of CYP2B6 and 
CYP3A via CAR/PXR. In vivo, lesinurad is neither an inhibitor nor an inducer of CYP2C9 and 2C8, 
but a mild to moderate inducer of CYP3A. CYP2B6 has not been studied in vivo.

Lesinurad is a substrate of OATP1B1, OAT1, OAT3 and OCT1. In vitro, lesinurad is an inhibitor of 
OATP1B1, OAT1, OAT3, OAT4 and OCT1 at clinically relevant plasma concentrations. However, 
the in vivo activity of OATP1B1, OAT1, OAT3 and OCT1 was not affected by lesinurad. Lesinurad is 
not an in vitro inhibitor of P-glycoprotein, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1 and 
MATE2-K.

Special populations

Renal impairment
The population pharmacokinetic analysis of clinical data in gout patients treated for up to 12 months 
estimated increases in lesinurad exposure of approximately 12%, 31% and 65% in patients with mild, 
moderate, and severe renal impairment, respectively, compared with patients with normal renal 
function.

Following administration of a single dose of lesinurad to individuals with renal impairment compared 
to those with normal renal function lesinurad Cmax and AUC, respectively, were 36% and 30% higher 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



14

(200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher 
(200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 
59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment 
(eCrCL <30 mL/min).

Hepatic impairment
Following administration of a single dose of lesinurad at 400 mg in patients with mild (Child-Pugh 
class A) or moderate (Child-Pugh class B) hepatic impairment, lesinurad Cmax was comparable and 
lesinurad AUC was 7% and 33% higher, respectively, compared to individuals with normal hepatic 
function. There is no clinical experience in patients with severe (Child-Pugh class C) hepatic 
impairment.

CYP2C9 poor metabolisers
Approximately half of an oral dose of lesinurad is cleared via CYP2C9 metabolism. The effect of 
CYP2C9 genotype on the pharmacokinetics of lesinurad was studied in 8 healthy subjects and 59 
patients with gout following daily dosing of lesinurad ranging from 200 mg to 600 mg in the absence 
or presence of a xanthine oxidase inhibitor. At the 400 mg dose, when compared with extensive 
CYP2C9 metabolisers (CYP2C9 *1/*1 [N=41]), increased lesinurad exposures were observed in 
intermediate CYP2C9 metabolisers (CYP2C9 *1/*3 [N=4], approximately 22% increase in AUC) and 
in poor CYP2C9 metabolisers (CYP2C9 *3/*3 [N=1], approximately 111% increase in AUC) 
accompanied with higher lesinurad renal excretion. However, individual values were well within the 
range observed in the extensive metaboliser subjects.

Patients who are known or suspected to be CYP2C9 poor metabolisers based on previous history or 
experience with other CYP2C9 substrates should use Zurampic with caution (see section 4.4).

Other special populations
Based on population pharmacokinetic analysis, age, gender, race and ethnicity do not have a clinically 
meaningful effect on the pharmacokinetics of lesinurad. Based on pharmacokinetic modelling 
simulations, patients with moderate renal impairment and reduced CYP2C9 activity (co-administration 
of a CYP2C9 inhibitor or a CYP2C9 poor metabolizer) are predicted to have an increase in AUC of 
approximately 200% in comparison to normal renal function and unimpaired CYP2C9 activity.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety 
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction 
and development. 

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
hypromellose
microcrystalline cellulose
lactose monohydrate
crospovidone type A
magnesium stearate

Tablet coat
hypromellose
titanium dioxide
triacetin
Indigo Carmine
Brilliant Blue FCF

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



15

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container 

Clear (PVC/PVDC/Aluminium) blister of 10 or 14 (calendar blister) tablets.
Pack sizes of 10, 28, 30, 98 in non-perforated blisters.
Pack size of 100 x 1 film-coated tablet in perforated unit dose blisters.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal. Any unused medicinal product or waste material should be 
disposed of in accordance with local requirements. 

7. MARKETING AUTHORISATION HOLDER

Grünenthal GmbH
Zieglerstr. 6
52078 Aachen
Germany
Tel.: +49-241-569-0

8. MARKETING AUTHORISATION NUMBER(S) 

EU/1/15/1080/001 10 film-coated tablets
EU/1/15/1080/002 28 film-coated tablets
EU/1/15/1080/003 30 film-coated tablets
EU/1/15/1080/004 98 film-coated tablets
EU/1/15/1080/005 100x1 film-coated tablets (unit dose)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18 February 2016

10. DATE OF REVISION OF THE TEXT

DD month YYYY

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



16

ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



17

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Grünenthal GmbH
Zieglerstr. 6
52078 Aachen
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
AUTHORISATION 

 Periodic safety update reports 

The requirements for submission of periodic safety update reports for this medicinal product are set 
out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 
2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this 
product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT

 Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the 
agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent 
updates of the RMP.

An updated RMP should be submitted:

 At the request of the European Medicines Agency;
 Whenever the risk management system is modified, especially as the result of new 

information being received that may lead to a significant change to the benefit/risk profile or 
as the result of an important (pharmacovigilance or risk minimisation) milestone being 
reached. 

 Obligation to conduct post-authorisation measures 

The MAH shall complete, within the stated timeframe, the below measures:

Description Due date
Non-interventional post-authorisation safety study (PASS): In order to investigate the 
cardiovascular risk in association with lesinurad exposure, mainly in patients with a 
history of cardiovascular disorders, the MAH shall conduct and submit the results of 
an observational prospective study according to an agreed protocol.

2Q 2019Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



18

ANNEX III

LABELLING AND PACKAGE LEAFLET

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



19

A. LABELLING

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



20

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Zurampic 200 mg film-coated tablets
lesinurad

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 200 mg lesinurad

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

10 film-coated tablets
28 film-coated tablets
30 film-coated tablets
98 film-coated tablets
100 x 1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



21

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Grünenthal GmbH
Zieglerstr. 6
52078 Aachen
Germany

12. MARKETING AUTHORISATION NUMBER(S) 

EU/1/15/1080/001 10 film-coated tablets
EU/1/15/1080/002 28 film-coated tablets
EU/1/15/1080/003 30 film-coated tablets
EU/1/15/1080/004 98 film-coated tablets
EU/1/15/1080/005 100x1 film-coated tablets (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

zurampic 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

<2D barcode carrying the unique identifier included.>

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

< PC: {number} 
SN: {number} 
NN: {number}>

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



22

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER NON-PERFORATED (10 TABLETS)
BLISTER PERFORATED UNIT DOSE
CALENDAR BLISTER (14 TABLETS)

1. NAME OF THE MEDICINAL PRODUCT

Zurampic 200 mg tablets
lesinurad

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Grünenthal GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

Mon. Tue. Wed. Thu. Fri. Sat. Sun.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



23

B. PACKAGE LEAFLET

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



24

Package leaflet: Information for the Patient

Zurampic 200 mg film-coated tablets
lesinurad

This medicine is subject to additional monitoring. This will allow quick identification of new 
safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you.
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 

effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Zurampic is and what it is used for 
2. What you need to know before you take Zurampic
3. How to take Zurampic
4. Possible side effects
5. How to store Zurampic
6. Contents of the pack and other information

1. What Zurampic is and what it is used for

Zurampic contains the active ingredient lesinurad and is used to treat gout in adult patients by lowering 
the levels of uric acid in the blood. Zurampic must be taken together with allopurinol or febuxostat, 
which are medicines called ‘xanthine oxidase inhibitors’ and are also used to treat gout by lowering 
the amount of uric acid in your blood.

Your doctor will prescribe Zurampic if your current medicine is not controlling your gout. You must 
use Zurampic together with either allopurinol or febuxostat.

How Zurampic works:
Gout is a type of arthritis caused by an accumulation of urate crystals around the joints. By lowering 
the amount of uric acid in the blood, Zurampic stops this accumulation and may prevent further joint 
damage.

2. What you need to know before you take Zurampic

Do not take Zurampic:
- if you are allergic to lesinurad or any of the other ingredients of this medicine (listed in section 

6)
- if you have ‘tumour lysis syndrome’ – a fast breakdown of cancer cells which can cause high 

uric acid levels
- if you have ‘Lesch-Nyhan syndrome’ – a rare inherited illness that starts in childhood where 

there is too much uric acid in the blood
- if your kidneys work very poorly or you have ‘End-Stage Kidney Disease’
- if you have received a kidney transplant
- if you are on kidney dialysis.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



25

Do not take Zurampic if any of the above apply to you. If you are not sure, talk to your doctor or
pharmacist before taking Zurampic.

Warnings and precautions
Talk to your doctor or pharmacist before taking Zurampic.

Look out for side effects
Zurampic may cause serious kidney problems (see section 4), which occur more frequently if 
Zurampic is taken alone (see section 3). Your doctor may ask you to have tests to check how your 
kidneys are working.

Tell your doctor before taking Zurampic if you have or have had heart failure or other heart problems.

If your gout gets worse
Some people may have more gout attacks (gout flares) when they start using Zurampic and during the 
first weeks or months of treatment. If this happens, keep taking Zurampic and talk to your doctor or 
pharmacist. The medicine is still working to lower uric acid. Over time, your gout attacks will happen
less often if you keep taking Zurampic as advised by your doctor. 

Your doctor may give you other medicines such as ‘colchicine’ and ‘nonsteroidal anti-inflammatory 
drugs (NSAIDs)’. These are to help prevent or treat the symptoms of gout attacks (a sudden or severe 
pain and swelling in a joint). Your doctor will tell you how long to take these other medicines for.

Tests and checks
Your doctor will check how well your kidneys are working before starting and during treatment with 
Zurampic. Your doctor may consider stopping Zurampic if your blood tests indicate changes in how 
your kidneys are working (blood creatinine levels increase) or if you experience symptoms of kidney 
problems. Your doctor may tell you to restart treatment with Zurampic when your kidney function 
improves.

Children and adolescents
Zurampic is not recommended for use in children and adolescents below 18 years of age.

Other medicines and Zurampic
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because Zurampic can affect the way some other medicines work. Also some other 
medicines can affect the way Zurampic works.

In particular, tell your doctor or pharmacist if you are taking any of the following medicines as they 
may interact with Zurampic and your doctor will need to know:

- acetylsalicylic acid – to relieve fever and pain - at doses above 325 mg per day
- medicines to treat high blood pressure, e.g. amlodipine
- medicines to treat high cholesterol levels, e.g. simvastatin
- fluconazole – to treat fungal infections
- amiodarone – to treat heart rhythm problems
- valproic acid, valpromide or carbamazepine – to treat fits (seizures), mood disorders and prevent 

migraines
- sildenafil – to treat erectile dysfunction
- contraceptives – used to prevent pregnancy, including oral contraception (such as ‘the pill’), 

injections, patches and implants
- rifampin – to treat tuberculosis
- warfarin – to prevent and treat blood clots forming in the legs, lungs, brain and heart.

If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking 
Zurampic.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



26

Pregnancy and breast-feeding
You should avoid taking Zurampic during pregnancy or if you are breast-feeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
Zurampic is not expected to affect you being able to drive a car or use any tools or machines.

Zurampic contains lactose
Zurampic tablets contain lactose (a type of sugar). If you have been told by your doctor that you have 
an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Zurampic

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.

Zurampic must always be taken together with your morning dose of either allopurinol or 
febuxostat. Failure to follow these instructions may increase the risk of kidney side effects (see 
section 4).

How much to take
The recommended dose is 1 tablet of 200 mg once a day in the morning. Do not take more than one (1) 
tablet of Zurampic per day.

Taking this medicine
- take in the morning with food and water
- take Zurampic at the same time as your morning dose of ‘xanthine oxidase inhibitor’ medicine –

allopurinol or febuxostat. If you take Zurampic on its own you may be more likely to get kidney 
problems

- drink plenty of water during the day. Two litres is a good amount to drink.

If you stop taking your xanthine oxidase inhibitor medicine, you must also stop taking 
Zurampic. Zurampic must never be taken without a ‘xanthine oxidase inhibitor’ medicine. Failure to 
follow these instructions may increase the risk of kidney side effects.

If you take more Zurampic than you should
If you take more of this medicine than you should, talk to a doctor or go to the nearest hospital.

If you forget to take Zurampic
If you miss a dose of Zurampic, do not take a double dose to make up for a forgotten dose. Wait and 
take your next dose of Zurampic with your next morning dose of allopurinol or febuxostat. Ask your 
doctor or pharmacist if you are not sure about how to take your next dose. 

If you stop taking Zurampic
Do not stop taking Zurampic without the advice of your doctor even if you feel better.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



27

Serious side effects – Uncommon – may affect up to 1 in 100 people
Stop taking Zurampic and see a doctor straight away if you notice any of the following side effects, as 
these may be signs of a problem with your kidneys – you may need urgent medical treatment:

- pain in your side (below your ribs and above your hipbone),
- feeling sick (nausea), being sick (vomiting),
- changes in urination or difficulty urinating,
- feeling tired or unwell or loss of appetite.

Other side effects include:
Common – may affect up to 1 in 10 people
- flu (influenza),
- headache,
- increase in the amount of creatinine in your blood - shown in tests,
- heartburn (acid reflux).

Uncommon – may affect up to 1 in 100 people
- kidney stones,
- dehydration (loss of too much fluid from your body).

Rare – may affect up to 1 in 1000 people
- skin reactions, including redness, itchy skin, lumpy rash (hives) and skin rash on exposure to 

sunshine.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.

5. How to store Zurampic

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister foil after “EXP”.
The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Zurampic contains
- the active substance is lesinurad.
- each Zurampic 200 mg film-coated tablet (tablet) contains 200 mg of lesinurad.
- the other ingredients are:
- tablet core: hypromellose, microcrystalline cellulose, lactose monohydrate (see section 2), 

crospovidone, magnesium stearate
- film-coating: hypromellose, titanium dioxide, triacetin, indigo carmine, brilliant blue FCF.

What Zurampic looks like and contents of the pack
Zurampic 200 mg: a blue, oval, dimensions 5.7 x 12.9 mm, film-coated tablet, engraved with 
“LES200” on one side.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



28

Zurampic 200 mg tablets are available in clear blisters in pack sizes of 10, 28, 30 or 98 non-perforated 
blisters and 100 x 1 perforated unit dose blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
Grünenthal GmbH
Zieglerstraße 6
52078 Aachen
Germany
Tel.: +49-241-569-0

For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:

België/Belgique/Belgien
S.A. Grünenthal N.V. 
Lenneke Marelaan 8
1932 Sint-Stevens-Woluwe
België/Belgique/Belgien
Tél/Tel: + 32 (0)2 290 52 00
beinfo@grunenthal.com

Lietuva
Grünenthal GmbH
Tel: + 49 241 569-0

България
Grünenthal GmbH
Teл.: + 49 241 569-0

Luxembourg/Luxemburg
S.A. Grünenthal N.V. 
Lenneke Marelaan 8
1932 Sint-Stevens-Woluwe 
België/Belgique/Belgien
Tél/Tel: + 32 (0)2 290 52 00
beinfo@grunenthal.com

Česká republika
Grünenthal GmbH
Tel: + 49 241 569-0

Magyarország
Grünenthal GmbH
Tel.: + 49 241 569-0

Danmark
Grünenthal Denmark ApS
Arne Jacobsens Allé 7
2300 København S
Tlf: +45 88883200

Malta
Grünenthal GmbH
Tel.: + 49 241 569-0

Deutschland
Grünenthal GmbH
Zieglerstr. 6

DE-52078 Aachen
Tel: + 49 241 569-1111
service@grunenthal.com

Nederland
Grünenthal B.V.
De Corridor 21K
NL-3621 ZA Breukelen
Tel:+31 (0)30 6046370 
info.nl@grunenthal.com

Eesti
Grünenthal GmbH
Tel: + 49 241 569-0

Norge
Grünenthal Norway AS
C.J. Hambros Plass 2C
0164 Oslo
Tlf: +47 22996054

Ελλάδα Österreich

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



29

Grünenthal GmbH
Τηλ: + 49 241 569-0

Grünenthal GmbH
Campus 21, Liebermannstraße A01/501
2345 Brunn am Gebirge
Tel: +43(0)2236 379 550-0

España
Grünenthal Pharma, S.A.
C/Dr. Zamenhof, 36
E-28027 Madrid
Tel: +34 (91) 301 93 00

Polska
Grünenthal GmbH
Tel.: + 49 241 569-0

France
Laboratoires Grünenthal SAS
Immeuble Eurêka
19 rue Ernest Renan
CS 90001
F- 92024 Nanterre Cedex
Tél: + 33 (0)1 41 49 45 80

Portugal
Grünenthal, S.A.
Alameda Fernão Lopes, 12-8.º A
P-1495 - 190 Algés
Tel: +351 / 214 72 63 00

Hrvatska
Grünenthal GmbH
Tel: + 49 241 569-0

România
Grünenthal GmbH
Tel: + 49 241 569-0

Ireland
Grünenthal Pharma Ltd
4045 Kingswood Road, 
Citywest Business Park
IRL – Citywest Co., Dublin
Tel: +44 (0)870 351 8960
medicalinformationie@grunenthal.com

Slovenija
Grünenthal GmbH
Tel: + 49 241 569-0

Ísland
Grünenthal GmbH
Sími: + 49 241 569-0

Slovenská republika
Grünenthal GmbH
Tel: + 49 241 569-0

Italia
Grünenthal Italia S.r.l.
Tel: +39 02 4305 1

Suomi/Finland
Grünenthal GmbH
Puh/Tel: + 49 241 569-0

Κύπρος
Grünenthal GmbH
Τηλ: + 49 241 569-0

Sverige
Grunenthal Sweden AB
Frösundaviks allé 15
169 70 Solna
Tel: +46 (0)86434060

Latvija
Grünenthal GmbH
Tel: + 49 241 569-0

United Kingdom
Grünenthal Ltd
1 Stokenchurch Business Park
Ibstone Road, HP14 3FE – UK
Tel: +44 (0)870 351 8960
medicalinformationuk@grunenthal.com

This leaflet was last revised in {MM/YYYY}.

Other sources of information

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



30

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu.

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET